Kornimate/medical-research-clean huggingface dataset:
impact of assistive forces on activities of daily living

Conditions: Spinal Cord Injury

Summary: this study is a cross-sectional study investigating the impact of assistive forces applied by the body-weight support system "the float" on the study participants. the study is conducted at the university hospital balgrist in zurich over a period of around 3 years. during this time measurements on approximately 140 able bodied subjects and 60 patients with an incomplete spinal cord injury will take place. the study participants are invited for a single visit of around 140 min duration to the university hospital balgrist. during this visit the study participants will repeatedly perform various activities of daily living (free walking, standing up and sitting down, stair climbing and balancing) with and without assistive forces from the body-weight support system. while performing the tasks, the study participants' motions and muscle activities will be measured to evaluate the naturalness of their movements. in addition, the collected data permits us to compare different movement patterns and make conclusions about effective and optimal movement support. obtaining this knowledge will help us to shape the therapy of these activities to be tailored to the patients and to train these movements with the help of the float under optimal conditions.


Eligibility criteria:
inclusion criteria: * individuals with incomplete spinal cord injury (ais c-d) or able bodied persons * informed consent as documented by signature * bodyweight \< 120 kg exclusion criteria: * a significant psychiatric or orthopedic diagnose * any secondary neurological complications that may impact the outcome variables * dermatological conditions (pressure ulcers, etc.) * pacemaker or other implanted, electronic devices * contraindications for float training * inability or unwillingness to provide written informed consent or follow study procedures e.g. due to language problems * psychological disorders, dementia, etc. * known or suspected non-compliance, drug or alcohol abuse * enrolment of the investigator, his/her family members, employees and other dependent persons
next generation cataract and vitreoretinal surgery study

Conditions: Ophthalmic Surgery

Summary: the purpose of this study is to obtain device-specific safety and performance clinical data to support marketability and to collect formal user feedback.

eligible subjects will be expected to attend 6 scheduled visits (day -30 to 0 screening, day 0 operative, day 1 postoperative, week 1 postoperative, month 1 postoperative, and month 3 postoperative) for a total individual duration for participation of approximately 4 months. one eye (study eye) will undergo ophthalmic surgery.

Eligibility criteria:
key inclusion criteria: * requires posterior segment surgery in the operating room with or without simultaneous cataract surgery; * clear media except for cataract and vitreous hemorrhage; * in simultaneous cataract and vitreoretinal surgery, eligible to undergo primary hydrophobic acrylic intraocular lens (iol) implantation into the capsular bag; * other protocol-defined inclusion criteria may apply. key exclusion criteria: * previous vitrectomy in the operative eye aside from those requiring silicone oil removal; * neovascular or uncontrolled glaucoma; * planned glaucoma or postoperative surgeries during study aside from silicone oil removal; * inadequate pupil dilation (less than 6 millimeters); * other protocol-defined exclusion criteria may apply.

Keywords: eye surgery cataract
a single-arm, open-label clinical study to evaluate the efficacy and safety of vrt106 in combination with chemotherapy for resectable pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of vrt106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.

this is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of vrt106 in combination with chemotherapy in the treatment of resectable pancreatic cancer. the study is planned to enroll 18 subjects. the entire study consists of a screening period of up to 28 days, treatment period, and a follow-up period (safety follow-up 28 days after the final study dose and survival follow-up once every 3 months).

Eligibility criteria:
inclusion criteria: 1. subject voluntarily agrees to participate in this study and signs an institutional review board -approved informed consent prior to performing any of the screening visit procedures. 2. males and females at 18-75 years of age, inclusive, at the screening visit. 3. have a clinical diagnosis of pancreatic cancer. 4. an eastern cooperative oncology group (ecog) score of 0 or 1. 5. expected survival time of≥6 months. 6. no serious hematologic and cardiac abnormalities of the liver, kidneys, or coagulation functions. exclusion criteria: 1. prior treatment with other oncolytic virus or systemic therapy for pancreatic cancer. 2. previous allogeneic hematopoietic stem cell transplantation or organ transplantation. 3. immunocompromised patients. 4. known alcohol or drug dependency. 5. women who are pregnant or breastfeeding.

Keywords: resectable pancreatic cancer
comparison of postoperative anal function between parks and bacon techniques in low rectal cancer

Conditions: Rectal Neoplasms; Low Anterior Resection Syndrome; Anastomotic Leak; Quality of Life

Summary: the goal of this study is to compare the postoperative anal function of patients with ultra-low rectal cancer after parks operation (colon anal anastomosis) and bacon operation (colon anal pull-out anastomosis), which may provide clinical evidence for the improvement of anal function and quality of life. the main questions it aims to answer are: the difference of anal function 1 year after surgery type of study: clinical trial participant population: patients with low rectal cancer participants will receive parks operation of bacon operation if there is a comparison group: researchers will compare parks and bacon operation to see if the anal function 1 year after surgery is different.

objective: to compare the postoperative anal function of patients with ultra-low rectal cancer after parks operation (colon anal anastomosis) and bacon operation (colon anal pull-out anastomosis), which may provide clinical evidence for the improvement of anal function and quality of life. primary outcome: low anterior resection syndrome (lars) score 1 year after surgery secondary outcomes: 1. lars score at 3 months after surgery 2. lars score at 6 months after surgery 3. postoperative quality of life score 4. the incidence of postoperative anastomotic complications

Eligibility criteria:
inclusion criteria: 1. men or women, aged between 18 and 75 years; 2. pathological diagnosis of rectal cancer before operation, with the distance from the lower edge of the tumor to the dentate line ≤ 3cm by mr imaging; 3. no local complications (including complete/ incomplete obstruction, active bleeding, local invasion of sphincter or levator ani, etc.) before operation; 4. suitable for anal preservation surgery discussed by mdt; 5. adequate bone marrow, liver, renal and cardiac function meeting the requirements of surgery and anesthesia; 6. r0 resection is expected technically; 7. provision of written informed consent. exclusion criteria: 1. previous history of malignant colorectal tumors; 2. complications such as obstruction and gastrointestinal bleeding that need an emergency operation; 3. unachievable r0 resection due to invasion of adjacent organs by primary tumor; 4. multiple primary tumors; 5. history of other malignancy; 6. participation in other clinical trials within the previous 4 weeks of enrollment; 7. asa physical status score ≥ iv level and/or ecog performance status ≥ 2; 8. intolerance of surgery due to liver, renal, cardiopulmonary or coagulation dysfunction, or underlying diseases; 9. history of serious mental disorders; 10. women in pregnancy or lactation period; 11. uncontrolled infection before operation; 12. unsuitable to be included due to other clinical and laboratory conditions by the judgement of investigators.

Keywords: anal function parks technique bacon technique
arizona prehospital cpr quality improvement project

Conditions: Out-of-Hospital Cardiac Arrest

Summary: the quality of cardiopulmonary resuscitation (cpr) provided to patients with out-of-hospital cardiac arrest (ohca) is often suboptimal. there now exist monitors/defibrillators that allow for the measurement and real time feedback of the quality of chest compressions and ventilations. in addition to giving the prehospital provider the benefit of real time cpr quality feedback via voice and visual cues, the cpr quality data acquired using these devices can be utilized as part of an on-going quality assurance/quality improvement program. the first objective of the proposed project is to quantify the quality of chest compressions and ventilations provided in the state of arizona to patients with ohca and to determine whether the quality of cpr is related to patient outcome from ohca. a second objective of this project is to determine whether use of audiovisual feedback improves both cpr quality and patient outcome in the pre-hospital setting.

phase i: in the first phase of the project, the ems systems will utilize the e-series units to treat all patients with ohca. the audiovisual feedback prompts will be inactivated during this phase. the ems providers will be instructed to follow the standard ccr protocol, as is currently the practice. aside from the change in monitor/defibrillator equipment, the treatment of ohca patients during this phase will be identical to the treatment that is currently performed. the quality of cpr will be measured using the accelerometer-based system. the data will be stored in the defibrillator and will be downloaded upon completion of the call. the first phase will be conducted for approximately 6 months from the time each site initiates the use of the e-series monitor/defibrillators. phase 2:in the second phase of the project, the ems providers will undergo training on how to use the audiovisual feedback prompts. the providers will continue to treat patients according to the ccr protocol but will now receive audio and/or visual feedback on the quality of cpr that they are performing. the providers will select the preferred feedback method(s) - audio, visual or both. as in phase i, the cpr data will be stored in the defibrillator and will be downloaded upon completion of the call. the total number of ems personnel who will be trained is approximately 450. in phase i, there were 219 ohcas (80% from mesa fire dept, and 20% from guardian medical transport). so far in phase ii, there have been about 100 ohcas.

Eligibility criteria:
inclusion criteria: * emergency medical services personnel at 8 fire departments in az who treat patients with out of hospital cardiac arrest (ohca) exclusion criteria: -

Keywords: out-of-hospital cardiac arrest, ohca
role of oral voriconazole in the treatment of resistant dermatophyte infections

Conditions: Dermatophyte Infection

Summary: treatment of dermatophyte infection in our country (pakistan) is becoming difficult due to the developing resistance to traditional antifungal agents. assessing the effectiveness ,feasibility and standard dosage of a newer antifungal drug like voriconazole is the need of the hour in resistant cases of dermatophyte infection.

treatment of dermatophyte infection in our country is becoming difficult due to the developing resistance to traditional antifungal agents. assessing the effectiveness and feasibility of a newer antifungal drug like voriconazole is the need of the hour in resistant cases. objective: to compare the efficacy of oral 200 milligram voriconazole once a day vs twice a day in the treatment of resistant dermatophyte infections (tinea corporis and cruris). material \& methods: this randomized controlled trial using non-probability sampling technique will be carried out in outpatient dermatology department, sheikh zayed hospital rahim yar khan, pakistan. approval from ethical review committee of the hospital has been taken. total 106 patients will be divided into two groups, group a and group b, each consisting of 53 patients. group a will be given oral voriconazole 200mg once a day and group b will be given twice a day for a maximum of 28 days. efficacy will be assessed at day 14 and day 28, and relapse will be noted at the 2-month follow-up visit. data will be recorded on a preformed proforma for each patient and wiil be analyzed using spss 24. a p-value of less than 0.05 will be considered statistically significant.

Eligibility criteria:
inclusion criteria: 1. resistant cases of tinea cruris and tinea corporis: those cases who received the standard dosage of oral antifungals i.e. oral terbinafine 5mg/kg per day for 4 weeks or oral itraconazole 5mg per/kg/day for 4 weeks but they did not recover from the infection. 2. skin area: groin and trunk 3. total diameter of the lesions: 5cm to 80 cm exclusion criteria: 1. history of hypersensitivity to azoles 2. all those individuals having immunocompromised state (malignancy, tuberculosis, aids, history of organ transplant and history of immunosuppressive drug treatment etc.) 3. patients of diabetes, liver or kidney disease. 4. lactating mother 5. pregnant female

Keywords: tinea voriconazole dermatomycoses antifungal agents
improving prostate lesion classification and development of a pi-rads 3 classifier

Conditions: Prostate Cancer

Summary: the investigators propose an ai methodology combining machine learning, histological results and expert image interpretation for the development of a pi-rads 3 classifier.

prostate cancer is the most common carcinoma in male patients in western industrialized countries. multiparametric prostate mri (mpmri) can select patients who may be potential candidates for biopsy. in this study, the investigators present a comprehensive methodology that evaluates a multitude of ai algorithms and assesses their performance on a large and high-quality dataset, aiming to generate an efficient model and develop a pi-rads 3 classifier. by combining the power of machine learning with the information provided by mpmri, histopathological results as well as expert image interpretation, the investigators attempt to improve the diagnostic accuracy, which in the future my lead to more informed clinical decisions and reduce unnecessary biopsies.

Eligibility criteria:
inclusion criteria: 1. only patients with a clinical indication for mp prostate mri will be included in this prospective study. 2. no allergies to gbca exclusion criteria: 1. contraindications for mri

Keywords: prostate cancer artificial intelligence
comparison of clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus (SLE)

Summary: systemic lupus erythematosus (sle) is a heterogeneous autoimmune disease with a highly variable presentation and course. it can affect virtually every organ of the body and many symptoms may be observed. skin, musculoskeletal, hematologic, and serological involvement are most commonly observed. some patients show predominately hematologic, renal, or central nervous system manifestations. studies have reported that juvenile-onset sle patients tend to have a more aggressive presentation and course, with higher rates of organ involvement and lower life expectancy than adult-onset sle patients. late-onset sle patients tend to have a more insidious onset of disease and tend to have less major organ involvement and more benign disease course. however, they have a poorer prognosis than patients who developed sle before the age of 50 years, because of the generally higher frequency of comorbid diseases and higher organ damage, due to aging and longer exposure to ''classical'' vascular risk factors. aims of the study: to compare clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of sle patients in our hospital.

methods: all patients will be subjected to the following: 1. thorough medical history of the patients 2. full clinical examination including: 1. general examination and vital signs. 2. complete rheumatological examination. 3. sle disease activity index sledai (ref). 4. slicc damage index (ref). 3. routine investigations (complete blood picture, erythrocyte sedimentation rate and liver functions). 4. renal investigations: 1. kidney functions 2. urine analysis 3. 24 hours protein in urine and/or a/c ratio 4. renal biopsy if indicated. 5. ana test. 6. ana profile for the most common 19 autoantibodies by immunoblot.

Eligibility criteria:
inclusion criteria: inclusion criteria: 1. patients diagnosed as sle( systemic lupus erythematosus )according to eular / ace (european league against rheumatism /american college of rheumatology ) 2. age juvenile sle ( systemic lupus erythematosus )was defined as a diagnosis below the age of 18 years, and those diagnosed between 19 and 50 years of age were classified as adult sle ( systemic lupus erythematosus ), late onset sle was defined as a diagnosis at more than 50 years of age). 3. patients with a disease duration of more than 6 months exclusion criteria: * exclusion criteria: 1. patients with had other autoimmune diseases, such as rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease , overlap syndrome or primary sjogren's syndrome ,but not secondary sjogren's syndrome or secondary antiphospholipid syndrome . 2. patients who are not willing to be involved in the study
study of posoleucel (alvr105,viralym-m) for multi-virus prevention in patients post-allogeneic hematopoietic cell transplant

Conditions: Adenovirus Infection; BK Virus Infection; Cytomegalovirus Infections; Epstein-Barr Virus Infections; Human Herpes Virus-6 Infection; JC Virus Infection

Summary: this is a phase 3 study to evaluate posoleucel (alvr105, viralym-m); an allogeneic, off-the-shelf multi-virus specific t cell therapy that targets six viral pathogens: bk virus, cytomegalovirus, adenovirus, epstein-barr virus, human herpesvirus 6 and jc virus.

this is a phase 2/3, multicenter, randomized, double-blind, placebo controlled trial comparing posoleucel to placebo for the prevention of infection or disease due to adv, bkv, cmv, ebv, hhv-6, or jcv in high-risk adult and pediatric patients after allogeneic hct. there are 2 parts to the study, a phase 3 randomized study cohort described in this posting, and an open label phase 2 cohort described in nct04693637, which has completed enrollment. in this phase 3 part, approximately 302 eligible allogeneic hct recipients will be enrolled and will receive 7 doses of posoleucel or placebo over 12 weeks, followed by a 12 week follow-up period.

Eligibility criteria:
key inclusion criteria: * any age at the day of screening visit. * no known or suspected clinically significant disease from adv, bkv, cmv, ebv, hhv-6, and/or jcv * within 25 days of receiving a first allogeneic hct and have demonstrated clinical engraftment at time of dosing * meet one or more of the following criteria at the time of randomization: * related (sibling) donor with at least one mismatch at one of these hla-gene loci: hla-a, -b or -dr * haploidentical donor * matched or mismatched unrelated donor * use of umbilical cord blood as stem cell source * ex vivo graft manipulation resulting in t cell depletion * received anti-thymocyte globulin or alemtuzumab (campath-1h) key exclusion criteria: * history of adv, bkv, cmv, ebv, hhv-6, and/or jcv end-organ disease within 6 months prior to randomization * evidence of active grade \>2 acute gvhd * presence of non-minor uncontrolled or progressive bacterial, viral or fungal infections * known history or current (suspected) diagnosis of grade ≥3 crs requiring treatment associated with the administration of peptides, proteins, and/or antibodies * ongoing therapy with high-dose systemic corticosteroids (ie, prednisone equivalent dose \>1.0 mg/kg/day) within 24 hours prior to dosing * relapse of primary malignancy other than minimal residual disease note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: allogeneic hematopoietic cell transplant alvr105 posoleucel viralym-m virus-specific t cells (vsts) cytotoxic t lymphocytes (ctls)
a study of ro5045337 in patients with liposarcomas prior to debulking surgery

Conditions: Sarcoma

Summary: this open-label study will evaluate efficacy, safety and tolerability of ro5045337 in patients with liposarcoma who are eligible for debulking surgery. prior to surgery, patients will receive 2-3 cycles of ro5045337, orally for 10 days followed by 18 days of rest per cycle. anticipated time on study treatment is 3 months. patients with an incomplete resection may be treated for an additional 3 cycles with ro5045337.


Eligibility criteria:
inclusion criteria: * adult patients, \>/=18 years of age * well differentiated and/or dedifferentiated liposarcoma eligible for tumor debulking surgery * willing to undergo tumor biopsies before, during and after treatment * ecog performance status 0-1 exclusion criteria: * previous chemotherapy and/or radiation for liposarcoma; previous debulking surgery is acceptable * patients receiving any other agent or therapy to treat their malignancy * patients requiring anticoagulant therapy and/or anti-platelet therapy * pre-existing gastrointestinal disorders which may interfere with absorption of drugs * history of seizure disorders or unstable cns metastases * clinically significant cardiovascular disease * history of long qt syndrome